Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

April 04, 2024 04:00 ET | Source: Grifols, S.A.

Procleix ArboPlex Assay® da Grifols recebe a marca CE, o primeiro e único NAT 4 em 1 para o rastreio de arbovírus

O teste de ácido nucleico in vitro da Grifols deteta quatro tipos de arbovírus, ajudando a reduzir o risco de infeções transmitidas por transfusãoOs arbovírus são uma ameaça emergente crescente, com...
April 04, 2024 04:00 ET | Source: Grifols, S.A.

Procleix ArboPlex Assay® di Grifols, primo e unico test NAT 4-in-1 per lo screening degli arbovirus, riceve il marchio CE

Il test NAT in vitro di Grifols rileva quattro tipi di arbovirus, contribuendo a ridurre il rischio di infezioni trasmesse tramite trasfusioneGli arbovirus sono una minaccia emergente in crescita,...
April 04, 2024 04:00 ET | Source: Grifols, S.A.

Grifols Procleix ArboPlex Assay® erhält die CE-Zertifizierung – der erste und einzige 4-in-1-Nukleinsäuretest zum Nachweis von Arboviren

Der In-vitro-Nukleinsäuretest von Grifols weist vier Arten von Arboviren nach und trägt dazu bei, das Risiko transfusionsbedingter Infektionen zu verringernArboviren stellen eine wachsende Bedrohung...
February 14, 2024 03:16 ET | Source: Grifols, S.A.

Grifols announces positive topline phase 3 fibrinogen clinical trial results

In the AdFIrst study, Biotest's fibrinogen concentrate (FC), BT524, met the primary endpoint, demonstrating its effectiveness in treating acquired fibrinogen deficiency (AFD) as equivalent to standard...
November 15, 2023 08:00 ET | Source: Grifols, S.A.

Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin Deficiency

Study designed to demonstrate impact of Alpha1-Proteinase Inhibitor Subcutaneous (Human) 15% (Alpha-1 15%), an alpha1 antitrypsin treatment, compared with Liquid Alpha1-Proteinase Inhibitor (Human)...
October 24, 2023 18:30 ET | Source: Grifols, S.A.

Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTAD

Trial met primary endpoints, confirming vaccine’s safety, tolerability and robust immune response against the Aβ40 peptide in early-stage Alzheimer's patientsABvac40 treatment slowed disease...
August 01, 2023 08:00 ET | Source: Grifols, S.A.

Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and Analytics

Grifols will apply artificial intelligence technologies, including large language models, to speed up the development of new biopharma therapeuticsAgreement is latest Grifols initiative to reinforce...
July 20, 2023 08:15 ET | Source: Grifols, S.A.

Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for Patients

Clinical trial met primary endpoint demonstrating comparable total immunoglobulin (Ig) levels when administering XEMBIFY® (Grifols’ subcutaneous Ig) every two weeks, compared with weekly, in patients...
July 18, 2023 08:00 ET | Source: Grifols, S.A.

Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated Cirrhosis

PRECIOSA clinical trial is designed to evaluate efficacy and safety of Grifols Albutein® plus standard medical treatment to increase survival time in patients with decompensated cirrhosis awaiting...
July 13, 2023 08:00 ET | Source: Grifols, S.A.

Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin Deficiency

Target of 339 patients enrolled has been met in the SPARTA clinical trial, designed to evaluate efficacy and safety of two separate weekly doses of Grifols’ Prolastin®-C (Alpha1-Proteinase Inhibitor...